Correlation Between Eli Lilly and Citius Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eli Lilly and Citius Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eli Lilly and Citius Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eli Lilly and and Citius Pharmaceuticals, you can compare the effects of market volatilities on Eli Lilly and Citius Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eli Lilly with a short position of Citius Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eli Lilly and Citius Pharmaceuticals.

Diversification Opportunities for Eli Lilly and Citius Pharmaceuticals

0.76
  Correlation Coefficient

Poor diversification

The 3 months correlation between Eli and Citius is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Eli Lilly and and Citius Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Citius Pharmaceuticals and Eli Lilly is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eli Lilly and are associated (or correlated) with Citius Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Citius Pharmaceuticals has no effect on the direction of Eli Lilly i.e., Eli Lilly and Citius Pharmaceuticals go up and down completely randomly.

Pair Corralation between Eli Lilly and Citius Pharmaceuticals

Considering the 90-day investment horizon Eli Lilly and is expected to generate 0.16 times more return on investment than Citius Pharmaceuticals. However, Eli Lilly and is 6.37 times less risky than Citius Pharmaceuticals. It trades about -0.07 of its potential returns per unit of risk. Citius Pharmaceuticals is currently generating about -0.36 per unit of risk. If you would invest  83,106  in Eli Lilly and on September 12, 2024 and sell it today you would lose (3,148) from holding Eli Lilly and or give up 3.79% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy95.45%
ValuesDaily Returns

Eli Lilly and  vs.  Citius Pharmaceuticals

 Performance 
       Timeline  
Eli Lilly 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eli Lilly and has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of sluggish performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Citius Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Citius Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Eli Lilly and Citius Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eli Lilly and Citius Pharmaceuticals

The main advantage of trading using opposite Eli Lilly and Citius Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eli Lilly position performs unexpectedly, Citius Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will offset losses from the drop in Citius Pharmaceuticals' long position.
The idea behind Eli Lilly and and Citius Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Valuation
Check real value of public entities based on technical and fundamental data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format